PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18667841-5 2008 Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression. SB 203580 206-215 interleukin 1 beta Mus musculus 13-21 14672714-6 2004 Additionally, specific inhibitors of SAPK/JNK and p38 MAP kinase, SP600125 and SB203580, also suppressed LPS-induced increase in IL-1beta gene expression and AP-1 DNA binding. SB 203580 79-87 interleukin 1 beta Mus musculus 129-137 17084586-8 2007 Blocking the activation of p38 MAPK as well as ERK 1/2 with specific inhibitors (SB203580 and U0126, respectively) down-regulated the IL-1beta expression. SB 203580 81-89 interleukin 1 beta Mus musculus 134-142 15048855-8 2004 The pharmacological agent SB203580 specifically blocked p38/SAPK2 activation, cytoplasmic translocation and reversed the IL-1beta and sorbitol-induced inhibition of GJC. SB 203580 26-34 interleukin 1 beta Mus musculus 121-129 15195698-10 2004 Western blot analysis confirmed that SB203580 inhibited p38 MAP kinase, in response to IL-1beta in a dose dependent manner in MC3T3-E1 cells. SB 203580 37-45 interleukin 1 beta Mus musculus 87-95 12609991-4 2003 Here we report that the inhibition of LTP induced by LPS and IL-1 beta was coupled with stimulation of the stress-activated protein kinase p38 in hippocampus and entorhinal cortex and that this effect was abrogated by the p38 inhibitor SB203580, while the effect of LPS was markedly attenuated in C57BL/6 IL-1RI-/- mice. SB 203580 236-244 interleukin 1 beta Mus musculus 61-70 10228013-2 1999 In this study, we examined the role of p38 MAPK in the regulation of the IL-1beta cytokine gene in monocytic cell lines using the bicyclic imidazole SB203580. SB 203580 149-157 interleukin 1 beta Mus musculus 73-81 10960082-12 2000 Interestingly, the inhibition of ERK kinase with PD 98059, as well as the inhibition of p38 MAPK with SB 203580, prevented IL-1beta-induced PGE(2) release. SB 203580 102-111 interleukin 1 beta Mus musculus 123-131 10228013-3 1999 Addition of SB203580 30 min before stimulation of monocytes with LPS inhibited IL-1beta protein and steady state message in a dose-dependent manner in both RAW264.7 and J774 cell lines. SB 203580 12-20 interleukin 1 beta Mus musculus 79-87 29448086-11 2018 Blocking the activation of p38 MAPK by SB203580 prevented elevation of IL-1beta and IL-17A induced by DIDP and OVA sensitization and effectively alleviated Th17 type asthmatic lesions. SB 203580 39-47 interleukin 1 beta Mus musculus 71-79 32626961-5 2020 SB203580 inhibited LPS-induced lung injury and proinflammatory cytokine expression, including tumor necrosis factor-alpha and interleukin-1beta. SB 203580 0-8 interleukin 1 beta Mus musculus 126-143 30152849-7 2018 However, blocking p38 MAPK signaling through the inhibitor SB203580 significantly suppressed the acute lung injury and excessive lung inflammation in vivo, consistent with the reduced expression of the NLRP3 inflammasome and IL-1beta and cleavage of caspase-1. SB 203580 59-67 interleukin 1 beta Mus musculus 225-233 9570551-7 1998 The specific p38 inhibitor SB203580 abrogated the mycoplasma-induced IL-6, IL-1beta, and TNF-alpha synthesis. SB 203580 27-35 interleukin 1 beta Mus musculus 75-83 29412160-6 2018 After adding p38 inhibitor, SB203580 to culture, the production of IL-1beta, IL-6, IL-10, TNF-alpha was significantly reduced as compared to visfatin only (P < 0.01). SB 203580 28-36 interleukin 1 beta Mus musculus 67-75 28603288-8 2017 Moreover, in LPS-stimulated mouse peritoneal macrophages, SB203580 strongly inhibited the restored expression of IL-1beta, IL-6, COX2, and MCP-1, which was achieved by abolishing the suppressive effects of osthole with the PKA inhibitors. SB 203580 58-66 interleukin 1 beta Mus musculus 113-121 23898520-11 2013 RESULTS: (1) The DAI scores, the levels of TNF-alpha and IL-1beta in SB203580 group were lower significantly compared with DSS group (P < 0.05), and were increased significantly compared with normal control group (P < 0.05). SB 203580 69-77 interleukin 1 beta Mus musculus 57-65 28155010-9 2017 Finally, pretreatment with p38 inhibitor, SB203580, attenuated the pIONL-induced mechanical allodynia and decreased the mRNA expression of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in the TG. SB 203580 42-50 interleukin 1 beta Mus musculus 220-237 28155010-9 2017 Finally, pretreatment with p38 inhibitor, SB203580, attenuated the pIONL-induced mechanical allodynia and decreased the mRNA expression of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in the TG. SB 203580 42-50 interleukin 1 beta Mus musculus 239-247 24885161-9 2014 SB203580 significantly attenuated lung inflammation (neutrophil infiltration, mRNA expressions of TNF-alpha and MIP-2, protein levels of KC, MIP-1alpha, IL-1beta, and IL-6), proteinase expression (MMP-12 mRNA), oxidative DNA damage, and apoptosis caused by acute CS exposure. SB 203580 0-8 interleukin 1 beta Mus musculus 153-161 23898520-12 2013 (2) The levels of TNF-alpha and IL-1beta in intestinal mucosal biopsy specimens in SB203580 treatment group were lower significantly than those in UC group (P < 0.05). SB 203580 83-91 interleukin 1 beta Mus musculus 32-40 23898520-13 2013 CONCLUSION: SB203580 can inhibit p38MAPK signal transduction pathway, then reduce the expression of pro-inflammatory cytokine TNF-alpha and IL-1beta. SB 203580 12-20 interleukin 1 beta Mus musculus 140-148 20956267-11 2010 IL-1beta, TNF-alpha, MMP-2 and MMP-9 mRNA levels were decreased in peritoneal cells of the SB203580 versus EM group (P < 0.01, P < 0.05, P < 0.05 and P < 0.05, respectively). SB 203580 91-99 interleukin 1 beta Mus musculus 0-8 20956267-12 2010 Concentrations of IL-1beta, TNF-alpha, MMP-2 and MMP-9 proteins in PF were reduced in the SB203580 versus EM group (P < 0.05, P < 0.01, P < 0.05 and P < 0.05, respectively). SB 203580 90-98 interleukin 1 beta Mus musculus 18-26 23827947-6 2013 SB203580 (p38 MAPK inhibitor) prevented IL-1beta-induced Cx43 upregulation. SB 203580 0-8 interleukin 1 beta Mus musculus 40-48 20178133-8 2010 RESULTS: Aurothiomalate inhibited IL-1beta-induced COX-2 expression and prostaglandin E(2) production by destabilizing COX-2 mRNA, as did the p38 MAPK inhibitor SB203580. SB 203580 161-169 interleukin 1 beta Mus musculus 34-42